Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
54,711,345
-
Number of holders
-
96
-
Total 13F shares, excl. options
-
20,216,239
-
Shares change
-
-18,207,669
-
Total reported value, excl. options
-
$680,314,450
-
Value change
-
-$703,085,149
-
Put/Call ratio
-
63.16%
-
Number of buys
-
51
-
Number of sells
-
-43
-
Price
-
$33.66
Significant Holders of Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK) as of Q2 2021
121 filings reported holding STOK - Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q2 2021.
Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK) has 96 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 20,216,239 shares
of 54,711,345 outstanding shares and own 36.95% of the company stock.
Largest 10 shareholders include RTW INVESTMENTS, LP (3,644,248 shares), Redmile Group, LLC (2,458,558 shares), FMR LLC (2,131,451 shares), VANGUARD GROUP INC (1,738,802 shares), BlackRock Inc. (1,515,399 shares), Cormorant Asset Management, LP (1,278,276 shares), GILDER GAGNON HOWE & CO LLC (1,245,956 shares), STATE STREET CORP (904,836 shares), FEDERATED HERMES, INC. (851,875 shares), and PERCEPTIVE ADVISORS LLC (671,978 shares).
This table shows the top 96 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.